NCT05539391 Optimisation Strategy for Emergency Tracheal Intubation
| NCT ID | NCT05539391 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bordeaux |
| Condition | Emergencies |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2023-01-14 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,500 participants in total. It began in 2023-01-14 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study has to objective to assess, in adults' patients needing tracheal intubation because of vital distress, the effect of a combined strategy to reduce intubation-related morbidity. This strategy will associate systematic use of rocuronium as paralyzing agent to facilitate tracheal intubation, bag face-mask ventilation before intubation and Gum Elastic Bougie (GEB) use.
Eligibility Criteria
Inclusion Criteria: * Patient adult (≥ 18 years) presenting with vital distress requiring emergency tracheal intubation as assessed by the emergency physician in the out-of-hospital setting. * Patient with all conditions (trauma, dyspnea, coma, overdoses, and shock) except those in cardiac arrest will be included. Exclusion Criteria: * Patient presenting of a contraindication to succinylcholine, and/or rocuronium, and/or sugammadex (rocunorium antagonist). * Patient who have contraindication to bag face mask ventilation before intubation (ongoing emesis, hematemesis, or hemoptysis). * Patient that are not members of a medical aid scheme (beneficiary or main member). * Patient under specific protection measures: pregnant, parturient or nursing women; legal protection or deprived of liberty: patient under judicial protection, patient under guardianship/curatorship.
Contact & Investigator
Xavier COMBES, Pr
PRINCIPAL INVESTIGATOR
Université Hospital, Bordeaux
Frequently Asked Questions
Who can join the NCT05539391 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Emergencies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05539391 currently recruiting?
Yes, NCT05539391 is actively recruiting participants. Contact the research team at xavier.combes@chu-bordeaux.fr for enrollment information.
Where is the NCT05539391 trial being conducted?
This trial is being conducted at Angers, France, Beaumont-sur-Oise, France, Bobigny, France, Bordeaux, France and 11 additional locations.
Who is sponsoring the NCT05539391 clinical trial?
NCT05539391 is sponsored by University Hospital, Bordeaux. The principal investigator is Xavier COMBES, Pr at Université Hospital, Bordeaux. The trial plans to enroll 1,500 participants.